Thymic malignancies: from clinical management to targeted therapies.
about
A phase I/II trial of belinostat in combination with cisplatin, doxorubicin, and cyclophosphamide in thymic epithelial tumors: a clinical and translational study.Thymic Epithelial Tumors phenotype relies on miR-145-5p epigenetic regulationMutations of epigenetic regulatory genes are common in thymic carcinomasWhole genome and transcriptome sequencing of a B3 thymoma.NUT rearrangement is uncommon in human thymic epithelial tumorsβ-catenin activation drives thymoma initiation and progression in miceOctreotide LAR and Prednisone as Neoadjuvant Treatment in Patients with Primary or Locally Recurrent Unresectable Thymic Tumors: A Phase II Study.18F-fluorodeoxyglucose positron emission tomography in the management of patients with thymic epithelial tumorsCopy number aberrations of genes regulating normal thymus development in thymic epithelial tumors.Circulating miR-21-5p and miR-148a-3p as emerging non-invasive biomarkers in thymic epithelial tumors.Tumor-related gene expression levels in thymic carcinoma and Type B3 thymomaThymoma patients treated in a phase I clinic at MD Anderson Cancer Center: responses to mTOR inhibitors and molecular analyses.Isolated splenic metastasis from a thymic carcinoma: A case report.Hepatic metastasis of thymoma: case report and immunohistochemical study.Advances in thymic carcinoma diagnosis and treatment: a review of literature.Expression of cell cycle and apoptosis regulators in thymus and thymic epithelial tumors.Targeted therapy for thymic epithelial tumors: a new horizon? Review of the literature and two cases reports.Gemcitabine in patients previously treated with platinum-containing chemotherapy for refractory thymic carcinoma: radiographic assessment using the RECIST criteria and the ITMIG recommendations.High expression of GRP78/BiP as a novel predictor of favorable outcomes in patients with advanced thymic carcinoma.PI3K as a Potential Therapeutic Target in Thymic Epithelial Tumors.Anti-Apoptotic Signature in Thymic Squamous Cell Carcinomas - Functional Relevance of Anti-Apoptotic BIRC3 Expression in the Thymic Carcinoma Cell Line 1889c.Molecular Profiling of Thymoma and Thymic Carcinoma: Genetic Differences and Potential Novel Therapeutic TargetsPrognostic effect of class III β-tubulin and Topoisomerase-II in patients with advanced thymic carcinoma who received combination chemotherapy, including taxanes or topoisomerase-II inhibitors.Metronomics for thymic carcinoma.ASXL1 and DNMT3A mutation in a cytogenetically normal B3 thymomaA specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors.Genomic Analysis of Thymic Epithelial Tumors Identifies Novel Subtypes Associated with Distinct Clinical Features.Thymic pathologies in myasthenia gravis: a preoperative assessment of CAT scan and nuclear based imaging.Protein expression and gene copy number changes of receptor tyrosine kinase in thymomas and thymic carcinomas.A comparative study of PD-L1 immunohistochemical assays with four reliable antibodies in thymic carcinoma.The genomic and epigenomic landscape in thymic carcinoma
P2860
Q33417499-0DC482BF-0BCD-4689-BFF3-81FDEE3E7406Q33655180-6102ADF4-AB15-4C42-B12F-4D7CA4E2FF67Q34648225-D657BAF2-1976-4035-85F2-3DC2D8435584Q34663810-0BD3A104-5005-41DF-85AE-B2C72094E6B9Q35840882-80B4D5CA-4053-4F52-A44C-6618ED3F0FFCQ35987257-7DE536DB-FD35-4579-8C09-46DCCCACC19FQ36228181-56AEDF3F-72C8-458E-82C1-01D3BFEBD94BQ36698218-7FFBD112-1B1F-4516-874C-B1469C30AA12Q36778107-6EE52524-D16F-492F-B9D2-3F1990C12C78Q36843755-93EB4EDC-D74D-40C8-ABAB-67F1F01201E8Q37076935-DB4EBDDB-9BFE-4E83-A91A-F69A499FEED4Q37132244-36B72517-87FF-4FCB-8FA5-81EC61F87012Q37283014-97CDA681-CF02-4E8E-9D33-F93C7261AE31Q37560517-8ED909E9-1023-4056-9448-BD23F5175962Q38218322-F6AE619E-F33A-4D45-8161-46DC61ED8B3CQ38385580-46B32604-E2F5-4AF1-985F-3B5C8F60B0FBQ38400475-CA92A69F-0CF5-41E7-8077-974F5E7F132FQ38662451-1E6CCAFF-FD90-4A4A-BF11-71E63BC3E97FQ38760585-3380D2E7-3E43-4E1C-B622-82EEF7263963Q38775158-9F4AD29E-9680-40BC-9C0F-1EC1362E7D72Q39034212-65AB9EB4-6364-4DAD-B778-75D29253CB3CQ41021890-A41EE5A8-E9D5-4F2A-8117-B35CB440E4E3Q41143898-5409E68A-EDD7-4100-8DB0-EEABCC1D6992Q41864696-4E45750A-AB3E-4921-A92A-5DAE8C2187FEQ42203445-57927770-87C6-4D6C-84D8-6877DDD4C31CQ47142579-92788F3C-1BAD-4A9B-BC0A-748A9924DCC5Q49643762-98E95DCE-D650-40E5-83D5-EEE668C5E1A2Q52985401-4674726E-75C8-4EEE-9AB4-8A9A62026365Q54504171-9D9FD068-B99A-4A51-A116-5DCF3D8B1FA1Q55229901-5C6F0201-43F8-4335-8F87-46E706B56059Q57700809-C63FED15-90E8-42EE-A285-F3625B70ACAB
P2860
Thymic malignancies: from clinical management to targeted therapies.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Thymic malignancies: from clinical management to targeted therapies.
@en
type
label
Thymic malignancies: from clinical management to targeted therapies.
@en
prefLabel
Thymic malignancies: from clinical management to targeted therapies.
@en
P2093
P2860
P356
P1476
Thymic malignancies: from clinical management to targeted therapies.
@en
P2093
Arun Rajan
Ronan J Kelly
Yisong Wang
P2860
P304
P356
10.1200/JCO.2011.36.0487
P407
P577
2011-11-21T00:00:00Z